Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > Articles online first > The Journal of Cardiovascular Surgery 2018 Apr 03

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

The Journal of Cardiovascular Surgery 2018 Apr 03

DOI: 10.23736/S0021-9509.18.10165-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Outcomes of Solo Smart valve in a single-center experience of 270 patients

Hao LIU 1, 2, Abbas KHANI-HANJANI 1, Siyuan YANG 1, 3, Wei WANG 1, Surita SIDHU 4, John MULLEN 1, Dennis MODRY 1, Shaohua WANG 1

1 Division of Cardiac Surgery, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada; 2 Cardiothoracic Department, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, P. R. China; 3 Department of Cardiac Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, P. R. China; 4 Department of Anesthesiology and Pain Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada


PDF  


BACKGROUND: The Solo Smart pericardial aortic valve has been widely used in Europe as an option for aortic valve replacement (AVR). We are reporting early and midterm clinical outcomes of AVR with the Solo Smart valve in a single North America center.
METHODS: This is a retrospective study of 270 consecutive patients who had AVR at Mazankowski Alberta Heart Institute from February 2011 to March 2015. Follow-up and echocardiographic data were collected retrospectively from electronic and paper charts. Univariate and multivariate analysis were performed to evaluate the results.
RESULTS: The mean age was 71.2±10.0 years, 67.4% were male, and 79.3% had combined procedures. Mean STS Score was 4.18±3.91. Early mortality was 3.7% for the entire group and 0% for isolated aortic valve replacement group. Mean cross-clamp time for isolated AVR and AVR with concomitant procedure was 70.8±12.7min and 117.0±45.0min, respectively. Permanent pacemaker implantation was necessary in 2.2% of patients. Echocardiography demonstrated a reduction in mean gradients from 40.8±17.4mmHg to 7.6±3.7 mmHg and peak gradient from 72.5 ± 48.8 mmHg to 15.5±7.5 mmHg. The 1-, 3-, and 5- year overall survival was 93.0%, 86.5% and 75.9%, respectively. At 5 years, freedom from valve-related death was 92.4%, freedom from structural valve deterioration and freedom from aortic valve reoperation were 96.4% and 98%, respectively.
CONCLUSIONS: The Solo Smart valve is safe and has excellent hemodynamic performance. Aortic valve reoperation and rates of valve-related adverse events during midterm follow-up were low.

inizio pagina

Publication History

Article first published online: April 3, 2018
Manuscript accepted: April 3, 2018
Manuscript revised: February 22, 2018
Manuscript received: August 13, 2017

Per citare questo articolo

Liu H, Khani-Hanjani A, Yang S, Wang W, Sidhu S, Mullen J et al. Outcomes of Solo Smart valve in a single-center experience of 270 patients. J Cardiovasc Surg 2018 Apr 03. DOI: 10.23736/S0021-9509.18.10165-0

Corresponding author e-mail

shaohua.wang@albertahealthservices.ca